
Valo is a technology company focused on accelerating drug discovery and development through the integration of human-centric data and AI-powered computation. Their Opal Computational Platform™ combines machine learning, tissue biology, and patient data to create powerful capabilities for drug discovery. The company has assembled a multidisciplinary team of software engineers, data scientists, biologists, and medicinal chemists to achieve its mission. Valo aims to transform data into valuable insights to speed up discoveries and advance its pipeline of programs, initially focusing on cardiovascular, metabolic, renal, oncology, and neurodegenerative diseases.

Valo is a technology company focused on accelerating drug discovery and development through the integration of human-centric data and AI-powered computation. Their Opal Computational Platform™ combines machine learning, tissue biology, and patient data to create powerful capabilities for drug discovery. The company has assembled a multidisciplinary team of software engineers, data scientists, biologists, and medicinal chemists to achieve its mission. Valo aims to transform data into valuable insights to speed up discoveries and advance its pipeline of programs, initially focusing on cardiovascular, metabolic, renal, oncology, and neurodegenerative diseases.
Founded: 2019
Headquarters / Region: Boston / Lexington, MA area
Core focus: AI-driven drug discovery using human-centric data (Opal Computational Platform)
Therapeutic areas: Cardiometabolic/renal, oncology, neurodegenerative diseases
Reported total funding: USD 460,000,000 (public profile figure)
Drug discovery and development inefficiencies; translating human data into actionable therapeutic candidates.
2019
Biotechnology Research
110000000
Announced $110M to close Series B
168500000
Fully committed PIPE associated with announced combination with Khosla Ventures Acquisition Co.
| Company |
|---|